The role of fibroblast growth factor 21 in the pathogenesis of liver disease: A novel predictor and therapeutic target

Expert Opinion on Therapeutic Targets

Volumn 18, Issue 11, 2014, Pages 1305-1313

  Liu, Wen Yue ^a   Huang, Sha ^a   Shi, Ke Qing ^a   Zhao, Chen Chen ^a   Chen, Li Li ^a   Braddock, Martin ^b   Chen, Yong Ping ^a   Feng, Wen Ke ^c   Zheng, Ming Hua ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b ASTRAZENECA   (United Kingdom)

^c University of Louisville School of Medicine   (United States)

Author keywords

Alcoholic liver disease; Endoplasmic reticulum stress; Fibroblast growth factor 21; Fibroblast growth factor 21 resistance; Hepatocellular carcinoma; Nonalcoholic fatty liver disease; Pathogenesis; Therapeutic target; Viral hepatitis

Indexed keywords

BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR 21; INSULIN; FIBROBLAST GROWTH FACTOR;

ADIPOSE TISSUE; ALCOHOL LIVER DISEASE; DRUG EFFECT; DRUG MECHANISM; EARLY INTERVENTION; ENDOPLASMIC RETICULUM STRESS; ENERGY EXPENDITURE; HUMAN; INSULIN SENSITIVITY; LIVER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER DISEASE; MUSCLE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PANCREAS; PATHOGENESIS; PREDICTION; PROTEIN EXPRESSION; REVIEW; THERAPY EFFECT; VIRUS HEPATITIS; VIRUS PATHOGENESIS; ANIMAL; DRUG DESIGN; ENERGY METABOLISM; INSULIN RESISTANCE; LIVER DISEASES; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BIOLOGICAL MARKERS; DRUG DESIGN; ENDOPLASMIC RETICULUM STRESS; ENERGY METABOLISM; FIBROBLAST GROWTH FACTORS; HUMANS; INSULIN RESISTANCE; LIVER DISEASES; MOLECULAR TARGETED THERAPY;

EID: 84910003771     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.944898     Document Type: Review

References (79)

1. Muise ES, Azzolina B, Kuo DW, et al. Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic states. Mol Pharmacol 2008;74(2):403-12
2. Cheung BM, Deng H. Fibroblast growth factor 21: a promising therapeutic target in obesity-related diseases. Expert Rev Cardiovasc Ther 2014;12(6):659-66
3. Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 2000;1492(1):203-6
4. Hondares E, Iglesias R, Giralt A, et al. Thermogenic activation induces FGF21 expression and release in brown adipose tissue. J Biol Chem 2011;286(15):12983-90
5. Oishi K, Konishi M, Murata Y, Itoh N. Time-imposed daily restricted feeding induces rhythmic expression of Fgf21 in white adipose tissue of mice. Biochem Biophys Res Commun 2011;412(2):396-400
6. Goetz R, Beenken A, Ibrahimi OA, et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 2007;27(9):3417-28
7. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009;8(3):235-53
8. Ding X, Boney-Montoya J, Owen BM, et al. betaKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab 2012;16(3):387-93
9. Foltz IN, Hu S, King C, et al. Treating diabetes and obesity with an FGF21-mimetic antibody activating the betaKlotho/FGFR1c receptor complex. Sci Transl Med 2012;4(162):162ra153
10. Ogawa Y, Kurosu H, Yamamoto M, et al. BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci USA 2007;104(18):7432-7
11. Potthoff MJ, Inagaki T, Satapati S, et al. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci USA 2009;106(26):10853-8
12. Xu J, Lloyd DJ, Hale C, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009;58(1):250-9
13. Wu C, Gilroy R, Taylor R, et al. Alteration of hepatic nuclear receptor-mediated signaling pathways in hepatitis C virus patients with and without a history of alcohol drinking. Hepatology 2011;54(6):1966-74
14. Yang C, Lu W, Lin T, et al. Activation of Liver FGF21 in hepatocarcinogenesis and during hepatic stress. BMC Gastroenterol 2013;13:67
15. Luo Y, McKeehan WL. Stressed liver and muscle call on adipocytes with FGF21. Front Endocrinol (Lausanne) 2013;4:194
16. Kharitonenkov A, Larsen P. FGF21 reloaded: challenges of a rapidly growing field. Trends Endocrinol Metab 2011;22(3):81-6
17. Kliewer SA, Mangelsdorf DJ. Fibroblast growth factor 21: from pharmacology to physiology. Am J Clin Nutr 2010;91(1):254s-7s
18. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011;141(5):1572-85
19. Tsukamoto H, Machida K, Dynnyk A, Mkrtchyan H. "Second hit" models of alcoholic liver disease. Semin Liver Dis 2009;29(2):178-87
20. Wilfred de Alwis NM, Day CP. Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin Liver Dis 2007;27(1):44-54
21. Fischer M, You M, Matsumoto M, Crabb DW. Peroxisome proliferator-activated receptor alpha (PPARalpha) agonist treatment reverses PPARalpha dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice. J Biol Chem 2003;278(30):27997-8004
22. Wan YJ, Morimoto M, Thurman RG, et al. Expression of the peroxisome proliferator-activated receptor gene is decreased in experimental alcoholic liver disease. Life Sci 1995;56(5):307-17
23. Badman MK, Pissios P, Kennedy AR, et al. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007;5(6):426-37
24. Inagaki T, Dutchak P, Zhao G, et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 2007;5(6):415-25.
25. Lundasen T, Hunt MC, Nilsson LM, et al. PPARalpha is a key regulator of hepatic FGF21. Biochem Biophys Res Commun 2007;360(2):437-40
26. Mai K, Andres J, Biedasek K, et al. Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21. Diabetes 2009;58(7):1532-8
27. Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005;115(6):1627-35.
28. Kharitonenkov A, Wroblewski VJ, Koester A, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007;148(2):774-81
29. Coskun T, Bina HA, Schneider MA, et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008;149(12):6018-27
30. Feng W, Liu Y, Zhao C, et al. Serum and hepatic fibroblast growth factor 21 (FGF-21) levels are increased in subjects with severe acute alcoholic hepatitis and in mice exposed to chronic-binge alcohol by decreased transcriptional suppression (abstract). Hepatology 2013;58(S1):480A
31. Mathews S, Xu M, Wang H, et al. Animals models of gastrointestinal and liver diseases. Animal models of alcohol-induced liver disease: pathophysiology, translational relevance, and challenges. Am J Physiol Gastrointest Liver Physiol 2014;306(10):G819-23
32. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006;43(2 Suppl 1):S99-S112
33. Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005;143(10):722-8
34. Malespin M, Sleesman B, Lau A, et al. Prevalence and correlates of suspected nonalcoholic fatty liver disease in Chinese American children. J Clin Gastroenterol 2014. [Epub ahead of print]
35. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288(21):2709-16
36. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010;51(5):1820-32
37. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129(1):113-21
38. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, et al. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009;58(11):1538-44
39. Milner KL, van der Poorten D, Xu A, et al. Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology 2009;49(6):1926-34
40. Feldstein AE, Wieckowska A, Lopez AR, et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009;50(4):1072-8
41. Li H, Dong K, Fang Q, et al. High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: a 3-year prospective study in China. J Hepatol 2013;58(3):557-63
42. Dushay J, Chui PC, Gopalakrishnan GS, et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010;139(2):456-63
43. Li H, Fang Q, Gao F, et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol 2010;53(5):934-40
44. Fisher FM, Chui PC, Antonellis PJ, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010;59(11):2781-9
45. Gaemers IC, Stallen JM, Kunne C, et al. Lipotoxicity and steatohepatitis in an overfed mouse model for non-alcoholic fatty liver disease. Biochim Biophys Acta 2011;1812(4):447-58
46. Jansen PL, van Werven J, Aarts E, et al. Alterations of hormonally active fibroblast growth factors after Roux-en-Y gastric bypass surgery. Dig Dis 2011;29(1):48-51
47. Chen WW, Li L, Yang GY, et al. Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2008;116(1):65-8
48. Zhang X, Yeung DC, Karpisek M, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008;57(5):1246-53
49. Fabbrini E, deHaseth D, Deivanayagam S, et al. Alterations in fatty acid kinetics in obese adolescents with increased intrahepatic triglyceride content. Obesity (Silver Spring) 2009;17(1):25-9
50. Li S, Meng F, Liao X, et al. Therapeutic role of ursolic acid on ameliorating hepatic steatosis and improving metabolic disorders in high-fat diet-induced non-alcoholic fatty liver disease rats. PLoS One 2014;9(1):e86724
51. Schaap FG, Kremer AE, Lamers WH, et al. Fibroblast growth factor 21 is induced by endoplasmic reticulum stress. Biochimie 2013;95(4):692-9
52. Lake AD, Novak P, Hardwick RN, et al. The adaptive endoplasmic reticulum stress response to lipotoxicity in progressive human nonalcoholic fatty liver disease. Toxicol Sci 2014;137(1):26-35
53. Zhang XQ, Xu CF, Yu CH, et al. Role of endoplasmic reticulum stress in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2014;20(7):1768-76
54. Kaplowitz N, Than TA, Shinohara M, Ji C. Endoplasmic reticulum stress and liver injury. Semin Liver Dis 2007;27(4):367-77
55. Malhi H, Kaufman RJ. Endoplasmic reticulum stress in liver disease. J Hepatol 2011;54(4):795-809
56. Misra P, Reddy JK. Peroxisome proliferator-activated receptor-alpha activation and excess energy burning in hepatocarcinogenesis. Biochimie 2014;98:63-74
57. Samson SL, Sathyanarayana P, Jogi M, et al. Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. Diabetologia 2011;54(12):3093-100
58. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362(9399):1907-17
59. Huang X, Yu C, Jin C, et al. Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis. Mol Carcinog 2006;45(12):934-42
60. El-Ashmawy NE, El-Bahrawy HA, Shamloula MM, El-Feky OA. Biochemical/metabolic changes associated with hepatocellular carcinoma development in mice. Tumour Biol 2014;35(6):5459-66
61. Wu X, Ge H, Lemon B, et al. FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. J Biol Chem 2010;285(8):5165-70
62. Fu L, John LM, Adams SH, et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004;145(6):2594-603
63. Tomlinson E, Fu L, John L, et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002;143(5):1741-7
64. Tinkle CL, Haas-Kogan D. Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics 2012;6:207-19
65. Sekar B, Newton PJ, Williams SG, Shaw SM. Should we consider patients with coexistent hepatitis B or C infection for orthotopic heart transplantation? J Transplant 2013;2013:748578
66. Kukla M, Berdowska A, Stygar D, et al. Serum FGF21 and RBP4 levels in patients with chronic hepatitis C. Scand J Gastroenterol 2012;47(8-9):1037-47
67. Li S, Ye L, Yu X, et al. Hepatitis C virus NS4B induces unfolded protein response and endoplasmic reticulum overload response-dependent NF-kappaB activation. Virology 2009;391(2):257-64
68. Grakoui A, Wychowski C, Lin C, et al. Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol 1993;67(3):1385-95
69. Ucar F, Sezer S, Ginis Z, et al. APRI, the FIB-4 score, and Forn's index have noninvasive diagnostic value for liver fibrosis in patients with chronic hepatitis B. Eur J Gastroenterol Hepatol 2013;25(9):1076-81
70. Wieckowska A, Feldstein AE. Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin Liver Dis 2008;28(4):386-95
71. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116(6):1413-19
72. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94(9):2467-74
73. Palmentieri B, de Sio I, La Mura V, et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis 2006;38(7):485-9
74. Guha IN, Parkes J, Roderick PR, et al. Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut 2006;55(11):1650-60
75. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121(1):91-100
76. Lee S, Jin Kim Y, Yong Jeon T, et al. Obesity is the only independent factor associated with ultrasound-diagnosed non-alcoholic fatty liver disease: a cross-sectional case-control study. Scand J Gastroenterol 2006;41(5):566-72
77. Hurjui DM, Nita O, Graur LI, et al. The central role of the non alcoholic fatty liver disease in metabolic syndrome. Rev Med Chir Soc Med Nat Iasi 2012;116(2):425-31
78. Zhu SL, Zhang ZY, Ren GP, et al. [Therapeutic effect of fibroblast growth factor 21 on NAFLD in MSG-iR mice and its mechanism]. Yao Xue Xue Bao 2013;48(12):1778-84
79. Alisi A, Ceccarelli S, Panera N, et al. Association between serum atypical fibroblast growth factors 21 and 19 and pediatric nonalcoholic fatty liver disease. PLoS One 2013;8(6):e67160